Johnson & Johnson (JNJ) : Money flow in the Johnson & Johnson (JNJ) stock was negative (43.38 million) on Wednesday, which shows that the investors used the strength in the stock price to reduce their holdings. The total traded value on upticks was $124.51 million, compared to $167.9 million on downticks. The total uptick to downtick ratio was 0.74, indicating the underlying weakness in the stock. Even in block trades, money flow was negative ($41.07 million), indicating selling on the strength. The transaction value during uptick in block trades was $7.17 million. Downtick transaction value in block trades amounted to $48.23 million, indicating persistent selling. The uptick to downtick ratio was 0.15. Johnson & Johnson (JNJ) traded $0.07 higher at $125.32 gaining 0.06% over the previous days close.
Also, Jefferies maintains their rating on the shares of Johnson & Johnson (NYSE:JNJ). The current rating of the shares is Hold. Equity Analysts at the Firm raises the price target to $113 per share from $109 per share. The rating by the firm was issued on July 14, 2016.
Johnson & Johnson (NYSE:JNJ): The stock opened at $125.84 on Wednesday but the bulls could not build on the opening and the stock topped out at $126.07 for the day. The stock traded down to $125.04 during the day, due to lack of any buying support eventually closed down at $125.14 with a loss of -0.09% for the day. The stock had closed at $125.25 on the previous day. The total traded volume was 7,334,633 shares.
The stock has recorded a 20-day Moving Average of 3.59% and the 50-Day Moving Average is 7.03%. In a related news, The officer (Exec VP, WW Chair, Med Devices), of Johnson & Johnson, Pruden Gary J had unloaded 9,735 shares at $116.03 per share in a transaction on June 7, 2016. The total value of transaction was $1,129,552. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.